Dr. Samip R. Master - Hematology ...

Dr. Samip Master

Claim this profile

LSU Health Sciences Center at Shreveport

Studies Multiple Myeloma
Studies Melanoma
5 reported clinical trials
13 drugs studied

Area of expertise

1

Multiple Myeloma

Samip Master has run 2 trials for Multiple Myeloma. Some of their research focus areas include:

Stage I
Stage II
Stage III
2

Melanoma

Samip Master has run 1 trial for Melanoma. Some of their research focus areas include:

Stage IV
Stage III
BRAF positive

Affiliated Hospitals

Image of trial facility.

LSU Health Sciences Center At Shreveport

Image of trial facility.

Ochsner LSU Health Monroe Medical Center

Clinical Trials Samip Master is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria

Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

More about Samip Master

Clinical Trial Related

4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Samip Master has experience with

  • Ipilimumab
  • Nivolumab
  • Dexamethasone
  • Lenalidomide
  • Sargramostim
  • Bortezomib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Samip Master specialize in?

Is Samip Master currently recruiting for clinical trials?

Are there any treatments that Samip Master has studied deeply?

What is the best way to schedule an appointment with Samip Master?

What is the office address of Samip Master?

Is there any support for travel costs?